HOWL logo

WEREWOLF THERAPEUTICS INC

HOWLNASDAQ
πŸ† #4501 by market capEarnings Nov 3US Equity
$0.91β–Ό $0.02 (βˆ’2.15%)
πŸŒ™ After hours$0.88β–Ό 3.27%Regular close Β· extended-hours price shown
πŸ””
Track HOWL
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 2.1%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$44M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-100.0%
Declining
πŸ“ŠGross Margin
86.4%
High
πŸ’΅FCF Margin
-143.6%
Thin
βš–οΈP/S Ratio
2.2x
Cheap
Otter Score
88
Very Good
No chart data available for HOWL.

Trading Snapshot

Day Range
$0.90 – $0.91
52-Week Range
$0.27 – $2.38
Volume
$3.17B
Avg Volume
$2.24B
Shares Outstanding
48.6M
Next Earnings
Nov 23, 2026

Fundamentals Snapshot

Annual Revenue
$21M
Last Q Revenue
$21M
P/E Ratio
-1.3
P/S Ratio
2.2x
EPS (TTM)
$-0.71
Dividend Yield
0.00%
Dilution (1yr)
+5.2%

Why Investors Own HOWL

  • βœ“High-growth profile β€” revenue up +56.0% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 63% gross margin and 17% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

HOWL logo

WEREWOLF THERAPEUTICS INC

HOWL
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0β–Ό βˆ’100.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
3.8%β–Ό βˆ’95.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$61Mβ–Ό βˆ’17.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$60Mβ–² +6.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
46.8Mβ–² +5.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$19Mβ–Ό βˆ’$55M YoY
StockOtter Β· stockotter.space

About WEREWOLF THERAPEUTICS INC

Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Very Good
88/100

Analyst Price Target

β“˜
Average Target
$1.04
β–² +13.9% Upside
High Target$1.23
Low Target$0.96
Based on 22 analysts

Latest News & Updates

GlobeNewsWireΒ·5d ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX)

BALA CYNWYD, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmit

GuruFocusΒ·20d ago

Are MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders?

Are MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Sept. 9, 2026

GlobeNewsWireΒ·20d ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)

BALA CYNWYD, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmit

GlobeNewsWireΒ·Aug 24

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX), CBIZ, Inc. (NYSE – CBZ)

BALA CYNWYD, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith

GuruFocusΒ·Aug 23

HOWL Stock Alert: Halper Sadeh LLC is Investigating Whether Werewolf Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Werewolf Therapeutics, Inc. (NASDAQ: HOWL) and Ambros Therapeutics, Inc. Upon clos

GuruFocusΒ·Aug 23

$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, TYFG and FULC

$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, TYFG and FULC PR Newswire